| Biography:
Paul Rachlin is a Partner in the Corporate Department, a member of the Firm’s Private Equity Practice Group, and a leader in the Firm’s Life Sciences practice area. Mr. Rachlin has over 20 years of experience in mergers and acquisitions and finance, representing clients in a broad range of transactions and industries.
Mr. Rachlin has unique experience representing medical device companies. Paul has represented dozens of medical device companies during their formative stages through later stage financings, and helped to navigate these companies through broad ranging strategic alternatives. Paul brings a highly multidisciplinary approach to the representation of emerging technology companies, and is experienced in guiding companies and investors in facing the myriad issues and pitfalls awaiting companies developing and commercializing new technologies.
Mr. Rachlin is an experienced securities lawyer, having represented underwriters and U.S. and non-U.S. issuers in private placements, 144A offerings, Regulation S offerings, and initial and secondary public equity offerings in the U.S. and abroad. Paul also has many years of experience representing underwriters and issuers in connection with Israeli-based technology companies.
Today, Paul is among the leading U.S. attorneys representing Israeli technology companies and U.S. and European investors in Israeli companies and the technologies developed by Israeli companies. Paul has traveled to Israel over 50 times during his more than 15 years of experience there, and maintains a continuing network of clients and contacts in this highly productive market for new technology companies.
Mr. Rachlin is based in Proskauer’s New York office. Paul graduated from Washington University School of Law in 1986, where he was the Executive Notes & Comments Editor of the Washington University Law Quarterly. He did his undergraduate work at the University of Vermont.
Transactions
Mr. Rachlin’s recent transactions, carried out with a team of highly skilled Proskauer attorneys, include the representation of:
- TransPharma Medical Ltd., an Israeli based company developing an innovative transdermal drug delivery system, in its exclusive license agreement of TransPharma's ViaDerm-hPTH (1-34) product to Eli Lilly and Company. TransPharma received $35 million in upfront payments, and may earn additional milestones and royalties based on the future development and commercial launch of the product;
- Ossur hf, a publicly traded Icelandic company, in the acquisition of Royce Medical, an orthotic products company, and in the recent sale of its silicon wound care division to BSN medical GmbH;
- Discotech Medical Technologies Ltd., an Israeli based medical device company, and its shareholders in the sale of its spine products business to Kyphon Inc. and DePuy Orthopedics, Inc.(a subsidiary of Johnson & Johnson) in combined transactions valued at over $240 million;
- WFD Ventures LLC and its shareholders in the sale of Hand Innovations LLC, an orthopedic medical device company, to DePuy Orthopedics, Inc., a subsidiary of Johnson & Johnson; and
- Ituran Location & Control Ltd., an Israeli technology company, in its initial public offering in the United States on NASDAQ.
|
